These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24893334)

  • 1. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs.
    Kurayoshi K; Ozono E; Iwanaga R; Bradford AP; Komori H; Ohtani K
    Biochem Biophys Res Commun; 2014 Jul; 450(1):240-6. PubMed ID: 24893334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectopic expression of the CDK inhibitor p21
    Kurayoshi K; Shiromoto A; Ozono E; Iwanaga R; Bradford AP; Araki K; Ohtani K
    Biochem Biophys Res Commun; 2017 Jan; 483(1):107-114. PubMed ID: 28042030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 8-Chloro-adenosine-induced E2F1 promotes p14ARF gene activation in H1299 cells through displacing Sp1 from multiple overlapping E2F1/Sp1 sites.
    Zhang HJ; Li WJ; Yang SY; Li SY; Ni JH; Jia HT
    J Cell Biochem; 2009 Feb; 106(3):464-72. PubMed ID: 19115249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity.
    Ozono E; Komori H; Iwanaga R; Ikeda MA; Iseki S; Ohtani K
    Genes Cells; 2009 Jan; 14(1):89-99. PubMed ID: 19077036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts.
    Ozono E; Komori H; Iwanaga R; Tanaka T; Sakae T; Kitamura H; Yamaoka S; Ohtani K
    Genes Cells; 2012 Aug; 17(8):660-72. PubMed ID: 22702391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
    Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
    Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
    Nakajima R; Zhao L; Zhou Y; Shirasawa M; Uchida A; Murakawa H; Fikriyanti M; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression.
    Komori H; Enomoto M; Nakamura M; Iwanaga R; Ohtani K
    EMBO J; 2005 Nov; 24(21):3724-36. PubMed ID: 16211008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts.
    Kitamura H; Ozono E; Iwanaga R; Bradford AP; Okuno J; Shimizu E; Kurayoshi K; Kugawa K; Toh H; Ohtani K
    Genes Cells; 2015 Sep; 20(9):739-57. PubMed ID: 26201719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.
    Nakajima R; Deguchi R; Komori H; Zhao L; Zhou Y; Shirasawa M; Angelina A; Goto Y; Tohjo F; Nakahashi K; Nakata K; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
    Biochem Biophys Res Commun; 2023 Jun; 663():154-162. PubMed ID: 37141667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation.
    Itoshima T; Fujiwara T; Waku T; Shao J; Kataoka M; Yarbrough WG; Liu TJ; Roth JA; Tanaka N; Kodama M
    Clin Cancer Res; 2000 Jul; 6(7):2851-9. PubMed ID: 10914734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
    Russell JL; Weaks RL; Berton TR; Johnson DG
    Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
    Majem M; Cascallo M; Bayo-Puxan N; Mesia R; Germa JR; Alemany R
    Cancer Gene Ther; 2006 Jul; 13(7):696-705. PubMed ID: 16498429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
    Aslanian A; Iaquinta PJ; Verona R; Lees JA
    Genes Dev; 2004 Jun; 18(12):1413-22. PubMed ID: 15175242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors.
    Parisi T; Pollice A; Di Cristofano A; Calabrò V; La Mantia G
    Biochem Biophys Res Commun; 2002 Mar; 291(5):1138-45. PubMed ID: 11883935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the Arf/p53 tumor surveillance network by E2F.
    Iaquinta PJ; Aslanian A; Lees JA
    Cold Spring Harb Symp Quant Biol; 2005; 70():309-16. PubMed ID: 16869767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
    Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
    Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity.
    Kurayoshi K; Okuno J; Ozono E; Iwanaga R; Bradford AP; Kugawa K; Araki K; Ohtani K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):784-790. PubMed ID: 27888102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.